NCT01265836撤回不适用
Dyslipidemia Treatment in Thailand and Cardiovascular Outcomes
适应症
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 发起方
- AstraZeneca
- 入组人数
- 1,064
- 主要终点
- The number (#) of subjects achieving the LDL-C goals according to updated 2004 NCEP ATP III guidelines.
研究概览
简要总结
The purpose of this study is to establish the proportion of patients on lipid-lowering pharmacological treatment (statin or combination) reaching the LDL-C goals according to the updated 2004 National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guidelines.
详细描述
MC MD
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provision of subject informed consent, Female or male aged = 18 years
- •Patients eligible for treatment of dyslipidemia with statins, according to the current guidelines NCEP ATPIII about Dyslipidemias and Atherosclerosis Prevention Receiving lipid-lowering drug treatment for at least 15 days.
排除标准
- •Involvement in the planning and conduct of the study (applies to either AstraZeneca staff or staff at the study site).
- •Previous enrolment or randomisation of treatment in the present study
- •Participation in a clinical study during the last 90 days
结局指标
主要结局
The number (#) of subjects achieving the LDL-C goals according to updated 2004 NCEP ATP III guidelines.
时间窗: 1 year
The percent (%) of subjects achieving the LDL-C goals according to updated 2004 NCEP ATP III guidelines.
时间窗: 1 year
次要结局
- The number of subjects achieving the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for several subject subsets(1 year)
- The number of the secondary event rate of cerebrovascular patients on lipid-lowering pharmacological treatment (statin or combination) who reaching and non-reaching the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for 1(1 year)
- The number of the secondary event rate cardiovascular patients on lipid-lowering pharmacological treatment (statin or combination) who reaching and non-reaching the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for 1 year(1 year)
- The percentage of subjects achieving the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for several subject subsets(1 year)
- The percent of the secondary event rate of cerebrovascular patients on lipid-lowering pharmacological treatment (statin or combination) who reaching and non-reaching the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for 1(1 year)
- The percent of the secondary event rate cardiovascular patients on lipid-lowering pharmacological treatment (statin or combination) who reaching and non-reaching the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for 1 year(1 year)
研究者
相似试验
已完成
不适用
Centralized Pan-Asian Survey on the Under Treatment of HypercholesterolemiaHypercholesterolemiaNCT00687492AstraZeneca8,000
已完成
不适用
Centralized Pan-Middle East Survey on the Under-treatment of Hypercholesterolemia, Sub-study for the Gulf StatesHypercholesterolemiaNCT01031277AstraZeneca1,000
已完成
不适用
Centralized Pan-Middle East Survey on the Undertreatment of HypercholesterolemiaHypercholesterolemiaNCT01025388AstraZeneca4,053
已完成
不适用
Centralized Pan-Russian Survey on the Undertreatment of HypercholesterolemiaDyslipidaemiaNCT01221584AstraZeneca1,000
已完成
不适用
Pan-European Survey on the Under Treatment of HypercholesterolemiaHypercholesterolemiaNCT00542867AstraZeneca6,500